GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Buyback Yield %

ARTV (Artiva Biotherapeutics) Buyback Yield % : -336.50 (As of Apr. 12, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Artiva Biotherapeutics's current buyback yield was -336.50%.


Artiva Biotherapeutics Buyback Yield % Historical Data

The historical data trend for Artiva Biotherapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Buyback Yield % Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial - - - - -66.29

Artiva Biotherapeutics Quarterly Data
Dec19 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -66.29

Competitive Comparison of Artiva Biotherapeutics's Buyback Yield %

For the Biotechnology subindustry, Artiva Biotherapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artiva Biotherapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Artiva Biotherapeutics's Buyback Yield % falls into.


;
;

Artiva Biotherapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Artiva Biotherapeutics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-4.183 + 166.507) / 244.86336
=-66.29%

Artiva Biotherapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-4.183 + 166.507) / 244.86336
=-66.29%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Artiva Biotherapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Artiva Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.